Heron Therapeutics (FRA:AXD2) Short Percentage of Float


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.38
GF Value €1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:AXD2 vs PLYX, ORMP, SPRO: Short Percentage of Float Comparison

For the Biotechnology subindustry, Heron Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heron Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Short Percentage of Float falls into.


FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.38 is trading 73.1% below its estimated GF Value™ of €1.40. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Short Percentage of Float:
  • GF Value™: €1.40 vs. price of €0.38 (73.1% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€1.40
GF Value